Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity
Jonathan Lam, … , Steven L. Teitelbaum, Daved H. Fremont
Jonathan Lam, … , Steven L. Teitelbaum, Daved H. Fremont
Published October 1, 2001
Citation Information: J Clin Invest. 2001;108(7):971-979. https://doi.org/10.1172/JCI13890.
View: Text | PDF
Article

Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity

  • Text
  • PDF
Abstract

RANK, the receptor activator of NF-κB, and its ligand RANKL (initially termed TRANCE, also termed ODF and OPGL), are a TNF superfamily receptor-ligand pair that govern the development and function of osteoclasts, lymphoid tissue, and mammary epithelium. While TNF family cytokines share a common structural scaffold, individual receptor-ligand pairs associate with high specificity. Given the low level of amino acid conservation among members of the TNF superfamily, the means by which these molecules achieve specificity cannot be completely understood without knowledge of their three-dimensional structures. To determine the elements of RANKL that mediate RANK activation, we have crystallized the ectodomain of murine RANKL and solved its structure to a resolution of 2.6 Å. RANKL self-associates as a homotrimer with four unique surface loops that distinguish it from other TNF family cytokines. Mutagenesis of selected residues in these loops significantly modulates RANK activation, as evidenced by in vitro osteoclastogenesis, thereby establishing their necessity in mediating the biological activities of RANKL. Such structural determinants of RANKL-RANK specificity may be of relevance in the pharmacologic design of compounds to ameliorate osteopenic disorders of bone.

Authors

Jonathan Lam, Christopher A. Nelson, F. Patrick Ross, Steven L. Teitelbaum, Daved H. Fremont

×

Total citations by year

Year: 2025 2024 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Total
Citations: 1 2 5 2 3 3 5 3 1 3 2 3 5 2 4 3 2 2 1 2 3 3 3 63
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (63)

Title and authors Publication Year
Leucine-Rich Repeat Kinase 1 Signaling Targets Proteins Critical for Endosome/Lysosome Sorting and Trafficking in Osteoclasts
Xing W, Chen Y, Udayakumar A, Zhao H, Mohan S
Biology 2025
Osteoclasts at Bone Remodeling: Order from Order.
Takito J, Nonaka N
Results and problems in cell differentiation 2024
Multiscale and multidisciplinary analysis of aging processes in bone
Ravazzano L, Colaianni G, Tarakanova A, Xiao YB, Grano M, Libonati F
2024
Receptor Specificity Engineering of TNF Superfamily Ligands
F Suo, X Zhou, R Setroikromo, W Quax
Pharmaceutics 2022
Effect on Osteoclast Differentiation and ER Stress Downregulation by Amygdalin and RANKL Binding Interaction.
Trang NM, Kim EN, Lee HS, Jeong GS
Biomolecules 2022
A Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases
Okagu IU, Ezeorba TP, Aguchem RN, Ohanenye IC, Aham EC, Okafor SN, Bollati C, Lammi C
International journal of molecular sciences 2022
Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis.
Huang D, Zhao C, Li R, Chen B, Zhang Y, Sun Z, Wei J, Zhou H, Gu Q, Xu J
Nature Communications 2022
Structural insights into the binding of zoledronic acid with RANKL via computational simulations
Wang R, Zhang W, Ma H, Zou D, Zhang Z, Wang S
Frontiers in Molecular Biosciences 2022
Modulating macrophage activities to promote endogenous bone regeneration: Biological mechanisms and engineering approaches
Y Niu, Z Wang, Y Shi, L Dong, C Wang
Bioactive Materials 2021
Identification of novel mutation in RANKL by whole‐exome sequencing in a Thai family with osteopetrosis; a case report and review of RANKL osteopetrosis
P Lertwilaiwittaya, B Suktitipat, P Khongthon, W Pongsapich, C Limwongse, M Pithukpakorn
Molecular Genetics & Genomic Medicine 2021
New perspectives on traumatic bone infections
RH Tang, J Yang, J Fei
Chinese journal of traumatology = Zhonghua chuang shang za zhi / Chinese Medical Association 2020
Mechanisms of RANKL delivery to the osteoclast precursor cell surface
M Honma, Y Ikebuchi, H Suzuki
Journal of Bone and Mineral Metabolism 2020
The role of the RANKL/RANK/OPG system in the central nervous systems (CNS)
R Hanada
Journal of Bone and Mineral Metabolism 2020
Creation of RANKL mutants with low affinity for decoy receptor OPG and their potential anti‐fibrosis activity
Y Wang, T Michiels, R Setroikromo, R Merkerk, RH Cool, WJ Quax
The FEBS journal 2019
Modification of the RANKL-RANK-binding site for the immunotherapeutic treatment of osteoporosis
Y Ko, G Lee, B Kim, M Park, Y Jang, W Lim
Osteoporosis International 2019
Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps
N Ogasawara, JA Poposki, AI Klingler, BK Tan, KE Hulse, WW Stevens, AT Peters, LC Grammer, KC Welch, SS Smith, DB Conley, JR Raviv, P Soroosh, K Takano, T Himi, RC Kern, RP Schleimer, A Kato
Mucosal Immunology 2019
Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice
M Shimamura, H Nakagami, H Shimizu, K Wakayama, T Kawano, Y Ikeda, H Hayashi, S Yoshida, H Mochizuki, R Morishita
BioMed Research International 2018
Comparative Characterization of Osteoclasts Derived From Murine Bone Marrow Macrophages and RAW 264.7 Cells Using Quantitative Proteomics: PROTEOMIC COMPARISON OF OSTEOCLAST MODELS
AY Ng, C Tu, S Shen, D Xu, MJ Oursler, J Qu, S Yang
JBMR Plus 2018
Recent advances in osteoclast biology
T Ono, T Nakashima
Histochemistry and Cell Biology 2018
Gadolinium Tagged Osteoprotegerin-Mimicking Peptide: A Novel Magnetic Resonance Imaging Biospecific Contrast Agent for the Inhibition of Osteoclastogenesis and Osteoclast Activity
L Mbundi, S Meikle, R Busquets, N Dowell, M Cercignani, M Santin
Nanomaterials 2018
The Tumor Necrosis Factor Superfamily Member RANKL Suppresses Effector Cytokine Production in Group 3 Innate Lymphoid Cells
JK Bando, S Gilfillan, C Song, KG McDonald, SC Huang, RD Newberry, Y Kobayashi, DS Allan, JR Carlyle, M Cella, M Colonna
Immunity 2018
Inflammatory osteolysis: A conspiracy against bone
Gabriel Mbalaviele, Deborah V. Novack, Georg Schett, Steven L. Teitelbaum
Journal of Clinical Investigation 2017
Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
G Melagraki, E Ntougkos, V Rinotas, C Papaneophytou, G Leonis, T Mavromoustakos, G Kontopidis, E Douni, A Afantitis, G Kollias, A MacKerell
PLoS computational biology 2017
Heterologous expression, purification and function of the extracellular domain of human RANK
Y Wei, Y Zhan, P Chen, Z Liu, H Zhang, D Liu, J Zhang, M Yu, W Mo, J Zhang, X Zhang
BMC Biotechnology 2017
A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke
H Kurinami, M Shimamura, H Nakagami, H Shimizu, H Koriyama, T Kawano, K Wakayama, H Mochizuki, H Rakugi, R Morishita
Scientific Reports 2016
A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis
C Liu, Y Zhao, W He, W Wang, Y Chen, S Zhang, Y Ma, J Gohda, T Ishida, TS Walter, RJ Owens, DI Stuart, J Ren, B Gao
Scientific Reports 2015
Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies
JT Higgs, JS Jarboe, JH Lee, D Chanda, CM Lee, C Deivanayagam, S Ponnazhagan
Molecular cancer research : MCR 2015
Principles of antibody-mediated TNF receptor activation
H Wajant
Cell Death and Differentiation 2015
Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members
JT Warren, CA Nelson, CE Decker, W Zou, DH Fremont, SL Teitelbaum
Science signaling 2014
Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL.
Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M
Oncotarget 2014
The role of TNF-α and TNF superfamily members in the pathogenesis of calcific aortic valvular disease
A Galeone, D Paparella, S Colucci, M Grano, G Brunetti
The Scientific World JOURNAL 2013
RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease
NL Iacono, A Pangrazio, M Abinun, R Bredius, M Zecca, HC Blair, P Vezzoni, A Villa, C Sobacchi
Clinical & developmental immunology 2013
Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions
I Nemčovičová, CA Benedict, DM Zajonc
PLoS pathogens 2013
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
DL Lacey, WJ Boyle, WS Simonet, PJ Kostenuik, WC Dougall, JK Sullivan, JS Martin, R Dansey
Nature Reviews Drug Discovery 2012
The Role of T-Cell Leukemia Translocation-Associated Gene Protein in Human Tumorigenesis and Osteoclastogenesis
S Kotake, T Yago, M Kawamoto, Y Nanke
Journal of Biomedicine and Biotechnology 2012
RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor
CA Nelson, JT Warren, MW Wang, SL Teitelbaum, DH Fremont
Structure 2012
Human receptor activator of NF-κB ligand (RANKL) induces osteoclastogenesis of primates in vitro
S Kotake, T Yago, M Kawamoto, Y Nanke
In vitro cellular & developmental biology. Animal 2012
Influence of Tumor Necrosis Factor  , Parathyroid Hormone, and Vitamin D3 on Modulation of the RANKL2 Isoform: A Pilot Study
SK Tat, JP Pelletier, C Ruiz-Velasco, M Padrines, Y Fortun, F Mineau, J Martel-Pelletier
Cartilage 2012
Role of osteoclasts and interleukin-17 in the pathogenesis of rheumatoid arthritis: crucial ‘human osteoclastology’
S Kotake, T Yago, M Kawamoto, Y Nanke
Journal of Bone and Mineral Metabolism 2011
A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway.
Raju R, Balakrishnan L, Nanjappa V, Bhattacharjee M, Getnet D, Muthusamy B, Kurian Thomas J, Sharma J, Rahiman BA, Harsha HC, Shankar S, Prasad TS, Mohan SS, Bader GD, Wani MR, Pandey A
Database : the journal of biological databases and curation 2011
Effects of NSAIDs on Differentiation and Function of Human and Murine Osteoclasts – Crucial ‘Human Osteoclastology’
S Kotake, T Yago, M Kawamoto, Y Nanke
Pharmaceuticals (Basel, Switzerland) 2010
Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis
HM Ta, GT Nguyen, HM Jin, J Choi, H Park, N Kim, HY Hwang, KK Kim
Proceedings of the National Academy of Sciences 2010
New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis
JC Crockett, DJ Mellis, DI Scott, MH Helfrich
Osteoporosis International 2010
Osteocyte Wnt/β-Catenin Signaling Is Required for Normal Bone Homeostasis
I Kramer, C Halleux, H Keller, M Pegurri, JH Gooi, PB Weber, JQ Feng, LF Bonewald, M Kneissel
Molecular and cellular biology 2010
Crystallization and preliminary X-ray analysis of mouse RANK and its complex with RANKL
TS Walter, C Liu, P Huang, S Zhang, LR Wedderburn, B Gao, RJ Owens, DI Stuart, P Tang, J Ren
Acta crystallographica. Section F, Structural biology and crystallization communications 2009
RANK, RANKL and osteoprotegerin in bone biology and disease
HL Wright, HS McCarthy, J Middleton, MJ Marshall
Current Reviews in Musculoskeletal Medicine 2009
Mutations within the TNF-Like Core Domain of RANKL Impair Osteoclast Differentiation and Activation
T Cheng, NJ Pavlos, C Wang, JW Tan, JM Lin, J Cornish, MH Zheng, J Xu
Molecular Endocrinology 2009
Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis
K Yasunori, T Masaaki, N Tetsuyuki, K Hayato, N Akira
Clinical Rheumatology 2008
Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: Influence of osteotropic factors
SK Tat, JP Pelletier, D Lajeunesse, H Fahmi, N Duval, J Martel-Pelletier
Bone 2008
Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
AE Kearns, S Khosla, PJ Kostenuik
Endocrine reviews 2007
Osteoclasts: What Do They Do and How Do They Do It?
SL Teitelbaum
The American Journal of Pathology 2007
A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption and bone loss
Kazuhiro Aoki, Hiroaki Saito, Cecile Itzstein, Masaji Ishiguro, Tatsuya Shibata, Roland Blanque, Anower Hussain Mian, Mariko Takahashi, Yoshifumi Suzuki, Masako Yoshimatsu, Akira Yamaguchi, Pierre Deprez, Ramachandran Murali, Keiichi Ohya, William C. Horne, and Roland Baron
Journal of Clinical Investigation 2006
FHL2 inhibits the activated osteoclast in a TRAF6 dependent manner
Shuting Bai, Hideki Kitaura, Haibo Zhao, Ju Chen, Judith M. Müller, Roland Schüle, Bryant Darnay, Deborah V. Novack, F. Patrick Ross, and Steven L. Teitelbaum
Journal of Clinical Investigation 2005
Osteoclasts; culprits in inflammatory osteolysis
SL Teitelbaum
Arthritis Research & Therapy 2005
gp130 Regulates Bone Turnover and Bone Size by Distinct Downstream Signaling Pathways
Natalie A. Sims, Brendan J. Jenkins, Julian M. W. Quinn, Akira Nakamura, Markus Glatt, Matthew T. Gillespie, Matthias Ernst, T. John Martin
Journal of Clinical Investigation 2004
RANKing c-Jun in osteoclast development
SL Teitelbaum
Journal of Clinical Investigation 2004
RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family
T Mori, A Oguro, T Ohtsu, Y Nakamura
Nucleic Acids Research 2004
The TNF Receptor Superfamily: Role in Immune Inflammation and Bone Formation
X Cheng, M Kinosaki, R Murali, MI Greene
Immunologic Research 2003
ΔBAFF, an Alternate Splice Isoform That Regulates Receptor Binding and Biopresentation of the B Cell Survival Cytokine, BAFF
AL Gavin, D Aït-Azzouzene, CF Ware, D Nemazee
The Journal of biological chemistry 2003
Mycobacterium tuberculosis Chaperonin 10 Heptamers Self-Associate through Their Biologically Active Loops
MM Roberts, AR Coker, G Fossati, P Mascagni, AR Coates, SP Wood
Journal of bacteriology 2003
Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation
W Huang, RJ O'Keefe, EM Schwarz
Arthritis Research & Therapy 2002
Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis
J Lam, Y Abu-Amer, CA Nelson, DH Fremont, FP Ross, SL Teitelbaum
Annals of the rheumatic diseases 2002
Bone destruction in arthritis
EM Gravallese
Annals of the rheumatic diseases 2002

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts